In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

This study analyzed the frequency and clinical significance of t(4;14)(p16;q32) in multiple myeloma (MM) among 208 patients with MM and 52 patients with monoclonal gammopathy of undetermined significance (MGUS); diagnosed between 1994 and 2001. Patients with the translocation were identified using reverse transcription-polymerase chain reaction (RT-PCR) to detect hybrid immunoglobulin heavy chain (IgH)-MMSET transcripts from the der(4) chromosome. We found 31 (14.9%) t(4;14)(+) MM patients and 1 (1.9%) t(4;14)(+) MGUS patient. IgH-MMSET hybrid transcripts were detected in bone marrow (BM) and blood. Breakpoint analysis revealed that 67.7% of t(4;14)(+) patients expressed hybrid transcripts potentially encoding full-length MMSET, whereas the remainder lacked one or more amino terminal exons. Expression of fibroblast growth factor receptor 3 (FGFR3), presumptively dysregulated on der(14), was detected by RT-PCR in only 23 of 31 (74%) patients with t(4;14)(+) MM. Patients lacking FGFR3 expression also lacked detectable der(14) products. Longitudinal analysis of 53 MM patients with multiple BM and blood samples showed that, over time, BM from t(4;14)(+) patients remained positive and that t(4;14)(-) patients did not acquire the translocation. IgH-MMSET hybrid transcripts and FGFR3 transcripts disappeared from blood during response to therapy. No correlation was observed between the occurrence of t(4;14) and known prognostic indicators. However, we find the t(4;14) translocation predicts for poor survival (P =.006; median, 644 days vs 1288 days; hazard ratio [HR], 2.0), even in FGFR3 nonexpressors (P =.003). The presence of t(4;14) is also predictive of poor response to first-line chemotherapy (P =.05). These results indicate a significant clinical impact of the t(4;14) translocation in MM that is independent of FGFR3 expression.

[1]  F. Gergely,et al.  The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. L. Bergsagel,et al.  The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. , 2001, Blood.

[3]  P. L. Bergsagel,et al.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. , 1998, Blood.

[4]  R. Egan,et al.  A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription. , 2001, American journal of respiratory cell and molecular biology.

[5]  P. L. Bergsagel,et al.  Multiple myeloma: increasing evidence for a multistep transformation process. , 1998, Blood.

[6]  A. Veronese,et al.  NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). , 2002, Blood.

[7]  J. Ihle,et al.  The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53‐regulated apoptosis , 2002, The EMBO journal.

[8]  B. Barlogie,et al.  Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. , 2001, Blood.

[9]  R. Bataille,et al.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.

[10]  P. L. Bergsagel,et al.  Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. , 2000, Blood.

[11]  R. Bataille,et al.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.

[12]  R. Bataille,et al.  Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. , 2001, Blood.

[13]  W. Kuehl,et al.  Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. , 2001, Blood.

[14]  L. Baldini,et al.  Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization. , 1999, Blood.

[15]  L. Baldini,et al.  Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. , 2000, Cancer research.

[16]  G. Morgan,et al.  A molecular study of the t(4;14) in multiple myeloma , 2002, British journal of haematology.

[17]  H. Johnsen,et al.  FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance , 2002, British journal of haematology.

[18]  G. Ahmann,et al.  Genomic abnormalities in monoclonal gammopathy of undetermined significance. , 2002, Blood.

[19]  R. Kyle,et al.  Monoclonal gammopathies of undetermined significance. , 2002, Reviews in clinical and experimental hematology.

[20]  Michael J. Lee,et al.  Msps/XMAP215 interacts with the centrosomal protein D-TACC to regulate microtubule behaviour , 2001, Nature Cell Biology.

[21]  L. Pilarski,et al.  A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. , 1998, Blood.

[22]  M. Taniwaki,et al.  Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies. , 2000, Cancer genetics and cytogenetics.

[23]  M. Taniwaki,et al.  The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. , 1997, Blood.

[24]  K. Thielemans,et al.  Evidence that the clonogenic cell in multiple myeloma originates from a pre‐switched but somatically mutated B cell , 1994, British journal of haematology.

[25]  T. Reiman,et al.  Intraclonal homogeneity of clonotypic immunoglobulin M and diversity of nonclinical post-switch isotypes in multiple myeloma: insights into the evolution of the myeloma clone. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  L. Axelsson,et al.  CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. , 1997, Blood.

[27]  R. Fonseca,et al.  Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. , 2002, Blood.

[28]  J. Cheng,et al.  A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. , 2001, Blood.

[29]  M. Hussein,et al.  Multiple myeloma: an overview of diagnosis and management. , 1994, Cleveland Clinic journal of medicine.

[30]  H Knecht,et al.  Centrosome defects and genetic instability in malignant tumors. , 1998, Cancer research.

[31]  E. Schröck,et al.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. , 1998, Blood.

[32]  B. Klein,et al.  Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma , 1997, Nature Genetics.

[33]  T. Reiman,et al.  Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. , 2001, Blood.

[34]  D. Gerhard,et al.  Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. , 1996, Blood.

[35]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[36]  A. Belch,et al.  Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Coluccia,et al.  Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. , 2001, The American journal of pathology.

[38]  A. Basten,et al.  Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. , 2001, Blood.

[39]  L. Baldini,et al.  Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14) , 2001, British journal of haematology.

[40]  Alan Wolfman,et al.  Cloning of TACC1, an embryonically expressed, potentially transforming coiled coil containing gene, from the 8p11 breast cancer amplicon , 1999, Oncogene.

[41]  P. L. Bergsagel,et al.  Chromosome translocations in multiple myeloma , 2001, Oncogene.

[42]  H. Ohkura,et al.  Msps protein is localized to acentrosomal poles to ensure bipolarity of Drosophila meiotic spindles , 2001, Nature Cell Biology.

[43]  L. Liotta,et al.  Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. , 2001, Cancer research.

[44]  B. Ness,et al.  The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell , 1993, The Journal of experimental medicine.

[45]  E. Schuuring,et al.  Visualization of mono-allelic chromosomal aberrations 3′ and 5′ of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization , 1997, Oncogene.

[46]  J. Cowell,et al.  The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. , 1999, Genomics.

[47]  M. Rocchi,et al.  A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. , 1997, Blood.

[48]  C. Heirman,et al.  Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. , 1992, Blood.